Bridging binder discovery and automated CAR T cell manufacturing: from CD19 to CLDN6
Bridging binder discovery and automated CAR T cell manufacturing: from CD19 to CLDN6
About the training
Despite the clinical success of CAR T cell therapies in hematologic malignancies, translating these approaches to solid tumors remains a significant challenge. This webinar follows the journey from CLDN6 binder discovery to CAR T cell generation and shows how these advances are prepared for clinical development using established manufacturing solutions on the CliniMACS Prodigy® Platform.
The session highlights how CLDN6-targeting binders are identified and converted into functional CAR T cells with activity against multiple solid tumors. It also demonstrates how an automated production process supports efficient scale-up and streamlined technology transfer when introducing new CAR constructs.
As the number of CAR T cell therapies grows, developing a new process for each construct adds complexity, cost, and delay. Standardizing steps within automated, functionally closed systems provides a scalable foundation that accelerates clinical translation for future programs, including those for solid tumors.
Agenda:
- Binder discovery: identifying and evaluating CLDN6-targeting binders
- CAR T cell development: from lead binder to potent CAR T cells
- Automated manufacturing: applying a closed, GMP-ready workflow on the CliniMACS Prodigy Platform
Presenters
Tanel Mahlakõiv, PhD
Director of Translational Research, Icosagen Cell Factory
Tanel Mahlakõiv, PhD, is a Director of Translational Research at Icosagen Cell Factory, leading the development of CAR T cell therapies and setting up GMP facilities and quality systems for manufacturing. He established a cell therapy consortium in Estonia to bring CD19 CAR T cell therapies to patients, and is advancing CLDN6-targeted therapies for solid tumors. Previously, he directed translational research at Celularity in New Jersey, USA, focusing on cellular immunotherapies.
Sophia Lollies
Global Product Manager, Miltenyi Biotec
Sophia Lollies is a Global Product Manager for the Clinical Engineered Cells portfolio at Miltenyi Biotec, driving strategy and commercialization initiatives for Cell & Gene Therapy solutions. She works closely with R&D and Clinical Development teams to advance gene-engineered T cell therapy enabling technologies and support the translation of CAR T cell innovations into clinical and commercial applications.
Watch the complete webinar for free
Your Miltenyi University benefits
Access online courses anytime, anywhere.
Become an expert in standard and innovative applications.
Acquire broad expertise and a comprehensive skill set.
Let us know your thoughts!
You did not find the course you are looking for? Do you have questions or comments?